Skip to content

Jobs updated Oct 23, 6:25 AM CT

COMPANY

Trishula Therapeutics

HQ: South San Francisco, CA source · trishulatx.com ↗ · West Coast

Clinical Phase 2

Keywords: oncology cancer antibody Pancreatic Cancer Lymphoma TTX-030

Location: South San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

Mar 25, 2024 Trial start 2: Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients source ↗
Mar 30, 2020 Trial start Phase 1: TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers source ↗
Apr 10, 2019 Trial start Phase 1: TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT06119217	Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients	2	Completed	Mar 25, 2024	Nov 17, 2025 (actual)
NCT04306900	TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers	Phase 1	Completed	Mar 30, 2020	Nov 30, 2022 (actual)
NCT03884556	TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers	Phase 1	Completed	Apr 10, 2019	Nov 30, 2022 (actual)